{"id":3656,"date":"2012-06-25T10:49:12","date_gmt":"2012-06-25T08:49:12","guid":{"rendered":"http:\/\/wproot.dti.supsi.ch\/m3\/?page_id=3656"},"modified":"2025-10-08T11:19:08","modified_gmt":"2025-10-08T10:19:08","slug":"news","status":"publish","type":"page","link":"https:\/\/m3.dti.supsi.ch\/index.php\/news\/","title":{"rendered":"News"},"content":{"rendered":"

Start of a new Innosuisse project: A Modular Gastroretentive AI-Refined Delivery System (GARDS) Platform Powered by Machine Learning for Optimised Oral Drug Delivery<\/strong>. Partners: IDSIA, ETHZ, FFHS, InkVivo Technologies AG<\/p>\n

——————————————————–<\/p>\n

Start of a new european Horizon project INJECTHEAL (2025, June 1st):
\n“Self-healing injectable hydrogel for chronic wound care and tissue regeneration”<\/strong><\/p>\n

INJECTHEAL is a Horizon Europe project focused on the development of a multifunctional self-healing injectable hydrogel designed to treat deep cavity chronic wounds and for supporting tissue regeneration. This novel hydrogel, based on functionalized pectin and gelatin, serves both as a therapeutic delivery vehicle and as a biomimetic matrix. It integrates antibacterial, anti-inflammatory, and pro-angiogenic-agents, offering a solution that can be injected directly into deep wounds \u2013 an approach currently unavailable with existing treatments. By doing so, it reduces the physical and mental burden associated with frequent bandage changes while ensuring effective action at otherwise hard-to-reach wound sites. To enable customizable bioactivity, INJECTHEAL employs poly(\u03b5-lysine) dendrons and incorporates polymeric microcapsules for controlled, targeted drug release. The project also addresses preclinical validation, industrial scalability, and the groundwork for clinical trials, paving the way toward real-world application.<\/p>\n

PROJECT CONSORTIUM<\/strong><\/p>\n

INJECTHEAL is funded by the European Union, through the Horizon Europe research and innovation programme under the Grant Agreement no. 101177924.\u00a0 The INJECTHEAL consortium is composed of 12 partners from 8 European countries (Italy, Austria, Germany, Ireland, Spain, Switzerland, and the United Kingdom). This partnership includes academic institutions, research centers, small and mediumsized enterprises, and industry organizations, united by the goal of advancing knowledge and applications in the field of chronic wound healing.<\/p>\n

——————————————————–<\/p>\n

The lab is organizing the second Annual Meeting of the COST action CA18103 Innogly<\/em> (Innovation with glycans), which will be held from 4th to 6th May 2022 at the new Campus Est USI SUPSI in via la Santa 1 in Lugano. More information can be found in the website of the conference:\u00a0\u00a0 https:\/\/innogly2022.eu<\/p>\n

——————————————————–<\/p>\n

We published on PNAS! Click on link to have more information:<\/p>\n

M. Serulla, G. Ichim, F. Stojceski, G. Grasso, S. Afonin, T. Schober, R. Roth, C. Godefroy, P.E. Milhiet, K. Das, A.G. Saez, A. Danani and C. Widmann, \u201cTAT-RasGAP 317-326 kills cells by targeting inner leaflet-enriched phospholipids\u201d, PNAS , DOI: 10.1073\/pnas.201410811 <\/a><\/p>\n

——————————————————–<\/p>\n

Download the program: Program Forum AI 09 October 2019<\/a>
\n——————————————————–
\nMyTalk:
\n“Elucidating the role of surface chemistry on cationic phosphorus dendrimer-siRNA complexation<\/em>“, Plenary Lecture at Biodendrimer 2018, Urbino, 4-7 June 2018
\n——————————————————–
\nPartecipation at SGE Investment Forum, Rohrschach, April 24th:
\n\"\"<\/p>\n

Presentation “Where AI and Big Data can help us to understand faster and better”<\/em>
\n\"\"<\/p>\n

Panel “Customer Focus and Transparency”<\/em> with Eric Jacob, Ruth Metzler and Sven Bradke
\n\"\"<\/p>\n

——————————————————–
\nMyTalk:
\n“Dendrimers as siRNA delivery systems and inhibitors of amyloids aggregation. A molecular modelling approach.” at ISN2A, Lisbon, 22-25 January 2018
\n\"\"
\n——————————————————–
\nNuovo Polo tecnologico in AI dell’UBS (notizie sui media e interviste, 17 gennaio 2918)<\/em><\/p>\n

RSI \u2013 Il Quotidiano (min 4.30 ca.) \u2013 19.00
\nLink: https:\/\/www.rsi.ch\/play\/tv\/il-quotidiano\/video\/17-01-2018-banche-e-tecnologia?id=10018859<\/a><\/em><\/p>\n

Teleticino \u2013 TGTalk \u2013 (min. 3.00 ca.) \u2013 19.45
\nLink (dal minuto 2:50): http:\/\/teleticino.ch\/programmi\/tg-talk\/tg-talk-17-01-2018-CE134172<\/a>
\n——————————————————-
\nMyTalk:
\n“Biocompatible Dendrimeric polymers to prevent amyloid-peptide fibril formation induced by CU(II): a multisciplinary study<\/em>” at Modern Trends in Dendrimer Chemistry and Applications, Moscow, 2-4 October 2017
\n——————————————————–
\nMyTalk:
\n“Molecular Modeling as virtual microscope: some examples with dendrimeric structures in interaction with siRNA, viruses and amyloids <\/em>“, seminar given in the Doctoral School at University of Sassari, 20 June 2017.
\n——————————————————–
\nMyTalk:
\n“How hybrid dendrimer nanoparticle affect amyloid \u03b1\u03b21-40 aggregation in presence of copper ions: a computational study<\/em>”
\nat “New Trends in nanomedicine”, International School of Nanomedicine, Erice, 8-13 April 2017
\n——————————————————–
\nPartecipation to Zuerich Economic Impulse<\/em>, Rueschlikon, 29 March 2017
\nPanel “Digitale Transformation”:<\/em><\/p>\n

\"ZH_Forum1\"
\n——————————————————–
\nMyTalk:
\n“Multiscale Approach for the Study of Ghrelin and Toll Like 7 Receptor Ligands<\/em>”
\nat the 1st MuTaLig COST Action Training School: Computational Approaches to Polypharmacology
\nPharmaziezentrum UZA2, University of Vienna, 8-10 February 2017
\nMC and WG meetings of COST Action CA15135
\n——————————————————–
\nCTI Project with Microsphere SA “Arcadia” approved!
\n31 January 2017
\n———————————————————-
\nMyTalk:
\n“Molecular Modeling as virtual microscope: some examples with dendrimers in interaction with siRNA, viruses and amyloids <\/em>”
\nat LCC-CNRS, Universit\u00e9 de Toulouse, 23 January 2017
\nand
\nat UMR CNRS 8612 Institut Galien Paris-Sud, 7 November 2016
\n——————————————————–
\nMC and WG meetings of COST Action MP1202, Aveiro (Portugal)
\n10 – 12 October 2016
\n——————————————————————————
\nMyTalk:
\n“Investigating the constitutive activity of Ghrelin Receptor by Molecular Modeling<\/em>”
\nat BMT 2016, “Dreil\u00e4ndertagung”, Swiss, Austrian \u2028and German Societies of Biomedical Engineering
\nCongress Center Basel, 4 \u2013 6 October 2016
\n——————————————————–
\nSER-COST project in collaboration with Universit\u00e9 Paris-Sud (Prof. E. Fattal) approved!
\n9 September 2016
\n——————————————————–
\nMyTalk:
\n“Optimization of gene and drug delivery systems using Molecular Dynamics: some examples<\/em>“,
\nat Swiss Physical Society- SPS Annual Meeting, USI – Lugano, 23 – 25 August 2016
\n———————————————————————————————————-
\nI joined on August 3d 2016 the Management Committee as MC substitute for Switzerland of the EU Cost Action CA 15135 \u201cMUTALIG\u201d.
\n———————————————————————————-
\nMyTalk:
\n“Investigating the constitutive activity of Ghrelin Receptor by Molecular Modeling<\/em>“,
\nat CECAM Workshop “Understanding function of proteins in membrane by atomistic and multiscale simulations”, USI- Lugano, 10 – 12 November 2015
\n——————————————————————————
\nMC and WG meetings of EU COST action MP1404, Parma,
\n12 – 13 October 2014
\n————————————————————
\nI joined on May 5th the Management Committee of the EU Cost Action MP 1404 \u201cSimulation and pharmaceutical technologies for advanced patient-tailored inhaled medicines (SimInhale)\u201d
\nand have been designated member of the steering committee as coordinator of Dissemination and Outreach of the Action
\n——————————————————————————–
\nTalks:
\n“Supporting the Design of Efficient Drug Nanocarriers with Molecular Modeling: some Examples”
\ngiven at:
\nSchool of Pharmaceutical Sciences (EPGL), University of Geneva, University of Lausanne, Biopharmaceutical Sciences, 5 December 2014, Geneva
\nand
\nNanostructured Functional Materials Group (NanoSFun), Centro de Investigaci\u00f3n en Nanociencia y Nanotecnologia (CIN2-CSIC), Institut Catal\u00e0 de Nanoci\u00e8ncia i Nanotecnologia (ICN2),
\n1 December 2014, Bellaterra (Barcelona), Spain
\n\"\"
\n————————————————————————————————————–
\n“Molecular Modeling to study and optimize Drug Delivery Systems”
\nat the 1st International Conference:
\n“From drug discovery to Drug Delivery”
\n13 \u2013 15 November 2014, Athens, Greece
\n————————————————————————————————————–
\n“Biofunctionalization Strategies of Magnetic Nanoparticles by Molecular Modeling ”
\nat the last Workshop of Cost Action “Bio-inspired nanotechnologies” TD1003:
\nBioinspired Materials Conference,
\n20-21 October 2014, Ankara, Turkey
\nBilkent University, Institute of Materials Science and Nanotechnology (UNAM)
\n—————————————————————————————————————————————————————————————-
\n“Molecular Modeling for Investigating Magnetic Nanoparticles Biofunctionalization Strategies”
\nat the Workshop of HINT Cost Action:
\nIntegrated approaches for biomolecular detection: nanostructures, biosensors and lab-on-chip devices
\n15 \u2013 17 September 2014, Istanbul, Turkey
\n\"Istanbul2014_FotoParticipants_small\"<\/a>
\n————————————————————————————————————–
\n\"140612_biodendrimer_striscione-1-page-001\"<\/a><\/em><\/p>\n

Pictures of the conference<\/a><\/em><\/p>\n

\"Clipboard01\"<\/a>
\nBiodendrimer 2014 – 4th International Symposium on Biomedical Applications of Dendrimers<\/a>
\nJune 18-20, Lugano, Palazzo dei Congressi
\n————————————————————————————————————–
\n“THE ROLE OF INTERACTING SURFACES IN INCREASING RECOGNITION AND BINDING AFFINITY OF AMYLOIDOGENIC JOSEPHIN DOMAINS: A MOLECULAR MODELING INVESTIGATION”
\nat the Workshop of Cost Action “Bio-inspired nanotechnologies” TD1003:
\nIntegrated approaches for biomolecular detection: nanostructures, biosensors and lab-on-chip devices
\n28 \u2013 30 aprile 2014, Scuola Superiore di Catania
\n\"catania\"<\/a>
\n—————————————————————————————————————-
\nSeminario SUPSI
\nTITLE: GPCR heterodimerization leads to opioid-induced hyperalgesia.<\/strong>
\nSPEAKER: Dr. Marino Convertino – University of North Carolina – Department of Biochemistry and Biophysics
\nDATE: Wednesday, 9 October 2013
\nPLACE: SUPSI-DTI, Galleria 2, Sala Primavera (Ground floor, Nord Entry)
\nTIME: 16.45-17.30
\nABSTRACT: Opioids are the most prescribed and effective drugs for treatment of moderate and severe pain. Despite their pharmacological efficacy, the use of opioids in therapy is compromised by the onset of significant side effects as opioid-induced hyperalgesia. We have recently discovered a new isoform of \u03bc-opioid receptor, which consists of six trans-membrane helices (6TM-mOR) that is able to dimerize with \u03b22 adrenergic receptor (b2AR). Upon migration on the cellular surface, the 6TM\/b2AR heterodimer is activated by morphine and leads to the development of severe opioid-induced hyperalgesia. Such finding can drive through the therapeutic use of classical beta-blockers in the treatment of chronic pain.
\n—————————————————————————————————————
\nIntervista al TG sul bosone di Higgs (8 ottobre 2013)
\nLink: Intervista al TG<\/a>
\n————————————————————————————————————————–
\nSeminario SUPSI
\nTITLE: A fusion of systems biology and physical structure approaches to rational drug design<\/strong>
\nSPEAKER: Dr. Avner Priel-\u00a0 University of Alberta – Edmonton, Canada
\nDATE: Wednesday, 31 July 2013
\nPLACE: SUPSI-DTI, Galleria 2, Room 230 (2nd floor)
\nTIME: 11.15-12.00<\/em><\/p>\n

ABSTRACT: In recent years two computational intensive approaches evolved; At the molecular level, in-silico rational drug design methods have been developed to suggest novel chemotherapeutic agents. The methods include compound library design, homology modeling, binding site prediction, etc. Binding affinity prediction is being performed with docking techniques, molecular dynamics, and hybrid quantum mechanics\/molecular mechanics approaches. At a higher level, the systems biology approach aims at modeling the highly interconnected nonlinear characteristics of biological systems. These efforts span many types of intra- and inter- cellular networks. I order to design and test in-silico new chemotherapeutic treatments, a fusion of both methods is required, allowing bottom-up and top-down feedback.<\/em><\/p>\n

————————————————————————————<\/em><\/p>\n

Prof. A. Danani: Partecipazione a Modem (RSI Radio svizzera – Rete Uno)
\nNanotecnologie: opportunit\u00e0 e rischi
\nPuntata del 4 giugno 2013
\nLink: Intervista a Modem-RSI<\/a>
\n—————————————————————————–
\nSeminario SUPSI\/NEUROCENTRO<\/em><\/p>\n

TITLE: Transcranial ultrasound (TUS) \u2013 A new therapy for brain disorders based on microtubule resonance?<\/strong>
\nSPEAKER: Stuart Hameroff \u2013 University of Arizona, Tucson, Arizona
\nDATE: Monday, June 3d, 2013
\nPLACE: Ospedale Civico Lugano, Neurocentro, Room 3, (floor -2)
\nTIME: 12.30 -13.30
\n—————————————————————————————————————–
\n“Consciousness in the Universe”<\/strong>
\nPublic seminar of Prof. Stuart Hameroff
\nDate: Sunday, June 2nd 2013, 18:00
\nPlace: Universit\u00e0 della Svizzera Italiana, Room A11, Via Buffi 13, Lugano
\nInformation: Seminar Hameroff June 2nd 2013<\/span><\/a>
\n—————————————————————————————————————–
\nLink: Andrea Danani on Personalised Medicine – YouTube<\/a>
\nInterviewed at the COST conference on Personalised Medicine, Andrea Danani, Professor, University Applied …
\n\u25ba 2:50
\n12\/lug\/2012 – Caricato da COSTOffice
\n\"larnaca\"<\/a>
\n————–<\/em><\/p>\n

\"\"<\/a><\/div>\n

LAMFI organized together with NAMED SA and Fondazione Canova the second international symposium entitled “Biophysical aspects of complexity in health ans disease”.<\/p>\n

For more details for programs and speakers , see: www.supsi.ch\/go\/bmp2012<\/p>\n

Press release Corriere del Ticino: (pdf)<\/span><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Start of a new Innosuisse project: A Modular Gastroretentive AI-Refined Delivery System (GARDS) Platform Powered by Machine Learning for Optimised Oral Drug Delivery. Partners: IDSIA, ETHZ, FFHS, InkVivo Technologies AG ——————————————————– Start of a new european Horizon project INJECTHEAL (2025, June 1st): “Self-healing injectable hydrogel …<\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":5,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-3656","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/m3.dti.supsi.ch\/index.php\/wp-json\/wp\/v2\/pages\/3656","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/m3.dti.supsi.ch\/index.php\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/m3.dti.supsi.ch\/index.php\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/m3.dti.supsi.ch\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/m3.dti.supsi.ch\/index.php\/wp-json\/wp\/v2\/comments?post=3656"}],"version-history":[{"count":41,"href":"https:\/\/m3.dti.supsi.ch\/index.php\/wp-json\/wp\/v2\/pages\/3656\/revisions"}],"predecessor-version":[{"id":6414,"href":"https:\/\/m3.dti.supsi.ch\/index.php\/wp-json\/wp\/v2\/pages\/3656\/revisions\/6414"}],"wp:attachment":[{"href":"https:\/\/m3.dti.supsi.ch\/index.php\/wp-json\/wp\/v2\/media?parent=3656"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}